Somalogic (SLGC) Reports Prelim FY21 Revenues of Over $79M

SomaLogic, Inc. (Nasdaq: SLGC), a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31^st, 2021.

Preliminary, unaudited revenue for the full year 2021 is expected to exceed $79 million, the upper end of SomaLogic’s previously raised 2021 revenue guidance range, representing over 41% year-over-year revenue growth.

“We are very pleased to announce these strong preliminary results which exceed our guidance and underscore the transformative year we had in 2021 – with robust growth, expanding scale, and over $630 million in new funding,” said Roy Smythe, M.D., Chief Executive Office of SomaLogic. “This year is already off to an incredible start with our announcement of an exclusive partnership with Illumina to develop NGS-based proteomic solutions, and we look forward to delivering on a number of important strategic milestones during 2022 and beyond. SomaLogic continues to be uniquely positioned to capture a significant share of the rapidly growing proteomics market and have an incredibly positive impact on biomedical research, healthcare, and human health.

Management will provide greater detail regarding its financial performance and outlook during its previously-announced Analyst & Investor Day on February 4^th , 2022, as well as during its fourth quarter and year-end 2021 earnings call to be held later this quarter.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c